OrthoLogic files PMA (premarket approval) supplement for spinal stimulator:
This article was originally published in Clinica
Executive Summary
OrthoLogic has filed a premarket approval (PMA) supplement with the US FDA for its SpinaLogic-1000 non-invasive device which stimulates spinal fusion. The device uses combined magnetic field technology to treat patients with spinal fusion in 30-minute daily treatments. If approved, it will be the Tempe, Arizona-based company's first entry into the spinal fusion market. The new supplement is based on the company's PMA for its OL-1000 bone growth stimulator, which received FDA approval in 1994.
You may also be interested in...
Biden Administration Is Setting An Example For Safe AI Use In Federal Organizations
A new memorandum by the Director of the Office of Management and Budget initiated a government-wide policy that will appoint AI officers to all agencies to address risks for AI use and serve as an example for greater AI adoption.
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.